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ABSTRACT
The truncated somatostatin receptor sst5TMD4 is associated with poor prognosis 
in breast cancer and increases breast cancer cell malignancy. Here, we examined the 
cellular/molecular mechanisms underlying this association, aiming to identify new 
molecular tools to improve diagnosis, prognosis or therapy. A gene expression array 
comparing sst5TMD4 stably-transfected MCF-7 cells and their controls (empty-plasmid) 
revealed the existence of profound alterations in the expression of genes involved in 
key tumoral processes, such as cell survival or angiogenesis. Moreover, sst5TMD4-
overexpressing MCF-7 and MDA-MB-231 cells demonstrated increased expression/
production of pro-angiogenic factors and enhanced capacity to form mammospheres. 
Consistently, sst5TMD4-expressing MCF-7 cells induced xenografted tumors with higher 
VEGF levels and elevated number of blood vessels. Importantly, sst5TMD4 was expressed 
in a subset of breast cancers, where it correlated with angiogenic markers, lymphatic 
metastasis, and reduced disease-free survival. These results, coupled to our previous 
data, support a relevant role of sst5TMD4 in the angiogenic process and reinforce the role 
of sst5TMD4 in breast cancer malignancy and metastatic potential, supporting its possible 
utility to develop new molecular biomarkers and drug therapies for these tumors.
INTRODUCTION
Cancer represents one of the most serious and 
complex health threats worldwide [1]. In particular, 
breast cancer is the most common tumor type in 
women and the second leading cause of death after 
lung carcinoma [1]. Unfortunately, the extraordinary 
variability, heterogeneity, and complexity of cancer, 
hampers the finding of common molecular elements, 
which could facilitate the development of more general 
and effective diagnostic and therapeutic strategies. In 
this regard, it has been established during the last years 
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that most cancers share a group of common hallmarks 
such as sustained proliferative signaling, evasion of 
growth suppressors, resistance to cell death, replicative 
immortality, angiogenesis, activation of invasion and 
metastasis, genome instability, inflammation, altered 
energy metabolism and evasion to immune destruction 
[2, 3]. More recently, it has been suggested the existence 
of additional common hallmark shared by all the 
tumoral pathologies as is the case of altered alternative 
splicing processes [4]. Indeed, recent studies point out 
that intratumoral heterogeneity in outcome and cancer 
survival can be explained, at least in part, by genetic 
variations (such as splicing variants) present in the 
primary tumor [5].
In line with this, our group has recently identified a 
new truncated variant of the somatostatin receptor subtype 
5, sst5TMD4, which is derived from a non-canonical 
splicing process [6], and is associated with the progression 
and/or malignancy of several endocrine-related tumors 
[6-12]. This truncated receptor was initially identified and 
characterized in pituitary adenomas [6], where its presence 
is associated to more aggressive features [8], and a poorer 
response to the classical medical therapy in this pathology, 
the somatostatin analogues [12]. Similarly, sst5TMD4 was 
also found to be overexpressed in poorly differentiated 
thyroid cancers, where it may explain the lack of response 
to somatostatin analogue treatment [9]. Most notably, 
sst5TMD4 presence was correlated with a worse prognosis 
in a group of breast cancers, and its overexpression was 
associated with increased malignant features in cell lines 
derived from breast tumors (MCF-7) [10]. Taken together, 
these results demonstrate a relevant role of the truncated 
receptor sst5TMD4 in several endocrine-related tumor 
pathologies wherein somatostatin or its analogs could be 
playing a regulatory role [11].
Based on these previous results, this study was 
aimed to attain a further understanding of the cellular 
and molecular mechanisms underlying the association 
between sst5TMD4 and bad prognosis and malignancy 
in breast cancer, with the ultimate goal of identifying 
new molecular targets with potential utility as 
biomarkers to improve diagnosis, predict prognosis or 
develop novel therapies in these tumors. To pursue this 
goal, we determined the gene expression microarray 
profiling of sst5TMD4-overexpressing MCF-7 cells, 
which, after functional enrichment analysis, revealed 
that several modified genes were tightly related, among 
other biological functions, to angiogenic process. 
Accordingly, we employed several relevant models, 
including in vitro cell lines, xenografted tumors and 
human breast cancer samples, to explore the association 
between the presence of the truncated receptor 
sst5TMD4 and the angiogenic process, as well as the 
possible relationship between this truncated receptor 
and relevant clinical features of the breast cancer 
patients.
RESULTS
sst5TMD4 overexpression alters the expression 
of angiogenesis-related genes in MCF-7 cells
A gene expression microarray comparing 
sst5TMD4-transfected MCF-7 cells with mock-transfected 
MCF-7 cells revealed an elevated number of genes 
altered by sst5TMD4 overexpression (38% up-regulated 
and 62% down-regulated) (Supplementary Table S1). 
Indeed, a software-driven functional-enrichment analysis 
of these data indicated that sst5TMD4 overexpression 
in MCF-7 alters the expression of numerous genes 
involved in relevant cellular processes such as epithelial 
to mesenchymal transition (EMT) (10% of altered genes 
with known function), cell growth (6%), cell metabolism 
(6%), signal transduction (13%), or, notably, angiogenesis 
(13%) (Figure 1A). Consistent with this analysis, it was 
previously demonstrated that sst5TMD4 overexpression 
could alter cell growth and EMT, among other tumor-
associated processes [10]. Conversely, its putative 
implication in the angiogenic process has not been 
explored hitherto. In support of the interest of exploring 
this issue, a user-driven functional-enrichment analysis 
of the data generated revealed that 31 out of 78 genes 
with known function (40%) significantly altered by the 
presence of sst5TMD4 were associated to the angiogenic 
process, based on the previous literature (Figure 1B and 
Supplementary Table S1). Further validation, by qPCR, 
of the genes that were altered in the gene expression 
microarray, confirmed the regulation of several 
angiogenesis-related genes in sst5TMD4-overexpressing 
MCF-7 cells, including the overexpression of ITGB2 or 
IGFBP1 (Figure 1C).
sst5TMD4 increases the production of 
pro-angiogenic factors and the capacity 
to form mammospheres in MCF-7 and 
MDA-MB-231 cells
In that the angiogenic process is driven by the 
expression and secretion of pro-angiogenic factors, 
the expression of the most relevant growth factors with 
angiogenic activity was determined in sst5TMD4-
expressing cells. In particular, sst5TMD4-transfected 
cells showed elevated levels of VEGF (p<0.05), EGF 
(p<0.05) and Ang1 (p<0.001), with no changes in Ang2 
expression, compared with mock-transfected cells (Figure 
1D). However, this elevation in the expression of pro-
angiogenic factors was not accompanied by an increase 
in the expression of hypoxia-induced genes such as HIF-
1a or HIF-1b (Figure 1D), whose elevation generally 
precedes those of the pro-angiogenic factors. Nevertheless, 
changes in protein expression or phosphorylation of 
these proteins cannot be ruled out. Consistent with these 
results, ELISA measurements revealed higher levels 
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Figure 1: sst5TMD4 expression is associated to higher expression of pro-angiogenic factors and higher capacity to 
form mammospheres in breast cancer MCF-7 cells. A. Software-driven functional analysis of genes whose expression is altered 
by the presence of sst5TMD4 in MCF-7 cells by gene expression microarray (green = inhibition, red = overexpression). B. User-driven 
supervised functional analysis of genes whose expression is altered by the presence of sst5TMD4 in MCF-7 cells by gene expression 
microarray (green = inhibition, red = overexpression). C. Examples of sst5TMD4-induced gene expression changes validated by additional 
qPCR in transfected cell lines. D. Changes in the expression of angiogenesis-related genes (VEGF, EGF, Ang1, Ang2, HIF1a and HIF1b) 
measured by qPCR in MCF-7 cells stably transfected with sst5TMD4 or pCDNA3.1 empty vector (mock). E. Levels of secreted VEGF 
in MCF-7 cells stably transfected with sst5TMD4 and mock controls measured by ELISA. F. Percentage and representative images of 
mammospheres formed from MCF-7 cells stably transfected with sst5TMD4 and the respective mock controls.Data represent mean ± SEM 
of n=3-6 independent experiments. Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate significant differences between sst5TMD4- and 
mock-transfected MCF-7 cells.
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of secreted VEGF in culture medium from sst5TMD4-
transfected cells compared to mock controls (Figure 1E), 
supporting the implication of sst5TMD4 in the elevated 
expression and secretion of angiogenic factors in MCF-7 
cells. Since angiogenesis in tumors seems to significantly 
derive from cancer stem-like cells (CSC)-secreted pro-
angiogenic factors [13-15], we aimed to determine the 
capacity of sst5TMD4-overexpressing MCF-7 cells to 
form mammospheres in low-adherence surfaces. This 
demonstrated that the presence of sst5TMD4 not only 
enhances the production of pro-angiogenic factors, 
but also increases the population of CSCs (Figure 1F), 
suggesting a role in maintaining the population of CSCs 
in breast cancer. Remarkably, the most relevant changes 
observed in MCF-7 were reproduced in an additional 
breast cancer cell model, the MDA-MB-231 cell line. 
Indeed, sst5TMD4-overexpressing MDA-MB-231 cells 
showed significantly elevated levels of two of the main 
pro-angiogenic factors (VEGF and EGF) and higher 
capacity to form mammospheres (Supplementary Figure 
S1), confirming the role of the truncated sst5TMD4 
receptors in the angiogenic process.
sst5TMD4 increases VEGF production and 
angiogenic features in an in vivo xenograft model
In order to confirm a relevant association between 
the expression of the truncated receptor and the 
angiogenic process in a preclinical model, we analyzed 
the expression of pro-angiogenic factors in xenograft 
tumors generated by the inoculation of sst5TMD4-
overexpressing MCF-7 cells in nude mice, as compared 
to mock transfected cells [10]. Consistent with the 
results obtained in vitro, these in vivo xenografted 
tumors induced by sst5TMD4-transfected cells (Figure 
2A) showed elevated VEGF and EGF expression levels 
(by qPCR; Figure 2B) and increased VEGF protein 
(detected by western-blot and immunohistofluorescence), 
as compared to tumors generated by the inoculation of 
mock-transfected cells (Figure 2B-2D). In addition, 
according with these results, tumors induced by 
sst5TMD4-overexpressing MCF-7 cells exhibited a 
clearly distinct phenotype, with significantly increased 
number of blood vessels per field (p<0.05, Figure 2E).
sst5TMD4 correlates with expression of 
angiogenic markers, lymphatic metastasis and 
disease-free survival in breast cancer patients
In order to explore the putative clinical consequences 
of sst5TMD4 presence, expression of this truncated 
receptor was determined by qPCR in a battery of 117 
grade 3 infiltrating ductal breast carcinoma tumors (IDC) 
tumors resected between 2003 and 2004, and patients 
were categorized as low- or high-sst5TMD4 expression 
levels according to the median sst5TMD4 expression, in 
order to further analyze the putative association between 
sst5TMD4 presence and angiogenic markers and clinical 
data (Figure 3). This analysis revealed a clear association 
between the expression levels of the truncated receptor 
sst5TMD4 and the expression of two of the most potent 
pro-angiogenic factors (VEGF and Ang1) and one of the 
most clinically-relevant angiogenic markers (CD34), as 
the group of high-sst5TMD4 expressing tumors presented 
higher average levels of VEGF (p<0.05), Ang1 (p<0,01) 
and a clear tendency also in CD34 (p=0.068) (Figure 
3A). Additionally, as might be expected, sst5TMD4 
expression was directly correlated with the expression of 
these angiogenic markers in the whole battery of breast 
cancer samples (Figure 3B), supporting a clear association 
between sst5TMD4 expression and the angiogenic 
process. Moreover, the presence of the truncated receptor 
sst5TMD4 was also linked to a greater probability to 
develop metastasis, in that a high proportion of the breast 
cancers that underwent lymphatic metastasis presented 
high sst5TMD4 expression [p=0.021], and a similar, 
non-significant tendency was found for distant metastasis 
[p=0.092] (Figure 3C and Supplementary Table S2). More 
importantly, sst5TMD4 expression was also associated 
to disease-free survival in breast cancer patients, since 
patients with high sst5TMD4 expression exhibited 
a markedly lower disease-free survival (p=0.015) 
(Figure 3D).
To further validate the association of truncated 
sst5TMD4 receptor with breast cancer aggressiveness, 
sst5TMD4 presence by immunohistochemistry was 
determined in these breast cancer samples using a TMA as 
described in Material and Methods. Representative images 
of some samples are shown in Figure 4A. Presence and 
expression of the sst5TMD4 receptor at the mRNA and 
protein levels were comparable [p=0.043] (Figure 4B and 
Supplementary Table S2). Interestingly, higher expression 
of sst5TMD4 at the protein level was also associated 
with CD34 positive tumors (p<0.001), with lymphatic 
metastasis (p=0.035) and with disease-free survival 
(p=0.058) (Figure 4C and Supplementary Table S2).
DISCUSSION
Malignant tumors are characterized by the clonal 
expansion of genetically abnormal cells exhibiting 
uncontrolled proliferation, failure to respond to 
homeostatic signals, invasion of adjacent tissues, and 
metastasis [3]. Angiogenesis plays a rate-limiting role 
in tumor growth since, in the absence of angiogenesis, 
tumors display a ‘dormant phenotype’, where cell 
proliferation reaches equilibrium with death [16]. Under 
certain conditions, tumor cells can secrete excessive 
proangiogenic factors that stimulate the sprouting of new 
vessels [17]. When the angiogenic process is turned on, 
the tumor subsequently grows and becomes more likely 
to metastasize [3]. Multiple growth factor pathways 
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Figure 2: sst5TMD4 overexpression increases the expression of pro-angiogenic factors and the number of blood 
vessels in xenografted breast cancer cell line-derived tumors. A. sst5TMD4 protein expression by western blotting in mock- and 
sst5TMD4-MCF-7 xenografted tumors. B. Expression levels of EGF and VEGF in xenografts derived from mock- and sst5TMD4-MCF-7 
cells measured by qPCR. C. and D. VEGF protein expression by western blotting and IHF in mock- and sst5TMD4-MCF-7 xenografted 
tumors. E. Representative images (x20) and quantification of straight blood vessels in xenografts derived from mock- and sst5TMD4-
MCF-7 cells. Data represent mean ± SEM of n=4-5 samples. Asterisks (*, p<0.05) indicate significant differences between sst5TMD4- and 
mock-transfected tumors.
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participate in this intricate process to regulate the growth 
and maintenance of blood vessels; among them, VEGF, 
EGF and angiopoietins (Ang1, Ang2) are particularly 
important [18-20]. Hence, angiogenesis is a critical 
process for tumor growth and invasion and has become a 
promising target in cancer therapy.
Somatostatin and its analogues (SSAs) have been 
shown to tightly control the angiogenic process. Indeed, 
SSAs were reported to reduce vascular cell proliferation 
[21] and to prevent hypoxia-induced changes in 
VEGF/VEGFRs system in vascular cells [22], likely 
through the sst1 and/or sst4 receptors [22]. In addition, 
Figure 3: sst5TMD4 expression is associated to higher expression of pro-angiogenic factors and the presence of 
lymphatic metastasis in breast cancer samples. A. Expression levels of VEGF, ANG1 and CD34 according to sst5TMD4 expression 
in the battery of 117 grade 3 infiltrating ductal breast carcinoma samples. Data represent mean ± SEM. B. Correlation between sst5TMD4 
expression and the expression of VEGF, ANG1 and CD34 in breast carcinoma samples. C. Association between the presence of sst5TMD4 
and lymphatic and distant metastasis in breast carcinoma samples. Graphs, obtained from a frequency table, show the distribution of 
117 grade 3 ductal breast carcinoma with low or high sst5TMD4 expression according to lymphatic and distant metastasis. D. Kaplan-
Meier plots showing the association between increased sst5TMD4 and disease-free survival (DFS) in breast carcinoma series. Significant 
correlation was studied using a Chi-square and Long-rank-p-value methods. Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate 
significant differences between samples with low and high sst5TMD4 expression.
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somatostatin and SSAs inhibit the angiogenic process 
in several models of retinal angiogenesis, likely acting 
through the sst2 receptor [23, 24]. Thus, and although 
much less is known about their role in tumoral cells, it 
seems that somatostatin and SSAs can reduce VEGF 
production from some types of tumoral cells such as 
gliomas [25], gastric carcinomas [26] or pancreatic 
cancer [27-29], acting through the sst2 receptor subtype 
[27-29]. Consistent with a role of somatostatin and its 
receptors in reducing the angiogenic process by acting 
at both, the endothelial cells and the tumoral cells levels 
[30], the use of SSAs in clinical trials has revealed that 
somatostatin could exert its anti-vasculogenesis effect by 
downregulating the serum VEGFs and, therefore, can be 
used as an important adjuvant to improve the survival of 
gastric cancer patients [26].
However, despite the fact that somatostatin receptors 
are densely expressed in breast cancer samples compared 
with normal tissues [31], being the sst2 subtype the 
most frequently and abundantly expressed in tumor cells 
[32], the clinical studies reporting treatment of breast 
cancer patients with SSAs have only demonstrated a 
limited success [33]. In this scenario, we have recently 
demonstrated that the presence of the truncated receptor 
sst5TMD4 correlates with a worse prognosis in a group 
of breast cancer tumors, and its overexpression is 
associated with increased malignant features such as 
invasion and proliferation abilities (both in cell cultures 
and nude mice) in breast cancer cell lines MCF-7 [10]. 
This was likely mediated by sst5TMD4-induced increase 
in phosphorylated ERK1/2 and Akt levels, which also led 
to mesenchymal-like phenotype. At the same time, this 
Figure 4: sst5TMD4 protein levels are associated to higher expression of pro-angiogenic factors and the presence of 
lymphatic metastasis in breast cancer samples. A. A TMA including the 117 breast carcinoma samples was employed to determine 
the presence of sst5TMD4 at the protein level by using an sst5TMD4 specific custom-made antibody and of the angiogenic marker CD34. 
Representative pictures (x20) of sst5TMD4 and CD34 staining in low and high sst5TMD4 expressors are depicted. B. Association between 
presence and expression of sst5TMD4 at protein and mRNA levels in the battery of breast carcinoma samples. C. Association between the 
presence of sst5TMD4 and CD34 and lymphatic metastasis in breast carcinoma samples. Graphs, obtained from a frequency table, show 
the distribution of 117 grade 3 breast carcinoma with low or high sst5TMD4 protein levels according to CD34 staining and lymphatic 
metastasis. D. Kaplan-Meier plots showing the association of increased sst5TMD4 by IHC and disease-free survival (DFS) in breast 
carcinoma series. Significant correlation was studied using a Chi-square and Long-rank-p-value methods.
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study demonstrated that sst5TMD4 interacts (physically 
and functionally) with sst2, promoting the disruption 
of somatostatin/sst2 inhibitory feedback. In the present 
study, we demonstrate that the presence of the sst5TMD4 
[6-12] induces significant changes in the expression of 
several angiogenesis-related genes and increases the 
expression and/or secretion of pro-angiogenic factors 
such as VEGF, EGF and/or angiopoietins in the breast 
cancer cell lines MCF-7 and MDA-MB-231, where it also 
increases the capacity to form mammospheres in culture. 
Moreover, sst5TMD4 induces the expression of relevant 
pro-angiogenic factors in a breast cancer xenografts 
model derived from this cell line, which translated into 
an increased number of blood vessels in the tumors. Of 
note, our previous results provide a plausible basis for 
the findings shown herein in that sst5TMD4 could be 
inducing VEGF expression/secretion through a direct 
(increasing phosphorylated ERK and Akt levels [34]) 
and/or an indirect mechanism (disrupting the inhibitory 
loop established between somatostatin and the sst2 [22, 
23, 28,29]). Interestingly, the expression array indicated 
that the changes in VEGF expression/secretion were 
accompanied by changes in the expression of some of its 
receptors (i.e. NRP2), which could indicate the existence of 
an autocrine/paracrine loop in sst5TMD4-overexpressing 
cells; but, surprisingly, were not accompanied by changes 
in the expression of HIF-1a and HIF-1b, which suggest 
that these factors are more likely regulated at the protein 
level (amount and/or phosphorylation status) or that 
sst5TMD4 increases VEGF expression through an HIF-
independent mechanism [35].
More importantly, the stimulatory role of sst5TMD4 
on the production of pro-angiogenic factors from MCF-
7 cells was accompanied by functional alterations in 
MCF-7 induced tumor xenografts. In particular, we 
have previously reported that sst5TMD4 overexpressing 
MCF-7 cells induce the formation of bigger xenograph 
tumors with a more undifferentiated phenotype [10]. In 
the present study, we expand those previous observations 
demonstrating that the presence of the sst5TMD4 receptor 
is associated with elevated production of pro-angiogenic 
factors (VEGF or EGF). Although we cannot rule out the 
possibility that other cell types present in the tumor could 
be contributing to these elevated levels of pro-angiogenic 
factors, the fact is that sst5TMD4-overexpressing cells 
induce tumors with higher number of blood vessels in the 
tumor, supporting its relevant role in tumoral angiogenic 
processes.
Angiogenesis is a crucial step for tumor growth 
and metastasis; however, tumor progression towards 
metastasis is a complex, multistage process, which is 
classically simplified as local invasion, intravasation, 
survival in the circulation, extravasation, and colonization 
[36]. Notwithstanding this, only about 0.2% of the tumor 
cells can effectively induce angiogenesis and eventually 
form metastases in distant organs [37]. In this context, 
cancer stem cells (CSCs) have been proposed to be 
the fundamental driving force of tumor development, 
initiation of invasion and metastasis [38]. Interestingly, as 
pointed earlier, the presence of the truncated sst5TMD4 
receptors could induce an enrichment of the CSC-like 
population, as suggested by the enhanced capacity of 
sst5TMD4-expressing cells to form mammospheres in 
vitro, which supports that sst5TMD4 would be involved in 
several processes required for tumor progression, invasion, 
and, ultimately, metastasis. As such, sst5TMD4 has been 
found to be expressed at moderate or high levels in a 
representative proportion (approximately 40%) of samples 
from a cohort of 117 grade 3 IDC, which is consistent 
with that previously published wherein sst5TMD4 was 
detected in 28% of 49 breast cancer samples from a closed 
random series of tumor breast samples classified as poorly 
differentiated grade 3 (G3) tumors [10]. In this new series 
of human IDC samples, sst5TMD4 presence/expression 
is associated to a higher expression of several angiogenic 
markers (VEGF, ANG1 or CD34) and to an elevated 
capacity of the tumors to metastasize, mainly to lymph 
nodes, suggesting that sst5TMD4 enhances the risk of 
lymphatic metastasis. And, most importantly, sst5TMD4 
presence/expression is associated with lower disease-free 
survival of patients, clearly reinforcing the notion that 
sst5TMD4 is involved in breast cancer malignancy and 
progression.
Thus, these results demonstrate that the mere 
presence of the truncated receptor sst5TMD4, which 
is overexpressed in a subset of breast cancer samples 
(herein and [10]), can directly or indirectly contribute to 
increase the capacity of the breast cancer cells to produce 
pro-angiogenic factors, thereby promoting the sprouting 
of new vessels, and facilitating tumor growth, which, in 
turn, makes them more prone to invade and metastasize. 
Consequently, when taken together, these and our previous 
discoveries support the notion that the presence/expression 
of the truncated receptor sst5TMD4 should be considered 
a risk factor for breast cancer progression, and therefore, 
that it could be used as a tool to identify novel, potentially 
valuable molecular biomarkers to improve the diagnosis 
and prognosis prediction for breast cancer, and as target to 
develop new drug therapies in these tumors.
MATERIALS AND METHODS
Breast cancer samples
The present study was performed using a total of 
117 infiltrating ductal breast carcinoma (IDC) tumors 
obtained from the archives of the Pathology Department 
of MD Anderson Cancer Center, Madrid (Spain) and 
initially described at Moreno-Bueno et al. [39]. All tumors 
were grade 3. Patients underwent surgery between 2003 
and 2004. The mean patient age at surgery was 54.9 
years (range, 27 to 79 years). According to the TNM 
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Classification staging, 48 of the tumors were stage I, 34 
were stage II, and 35 were stage III-IV. Two different 
tumor areas from each sample were included into a 
tissue microarray (TMA) according to manufacturer’s 
procedures. Histological and immunohistochemical studies 
were all carried out on formalin-fixed, paraffin-embedded 
tissue samples. Clinical data of the tumor sample are 
provided in Supplementary Table S3. This study was 
performed following standard ethical procedures of 
the Spanish regulation (Ley de Investigación Orgánica 
Biomédica, 14 July 2007) and was approved by the ethic 
committee of MD Anderson Cancer Center, Madrid, 
Spain.
Cell lines
MCF-7 and MDA-MB-231 breast cancer cell lines 
(ATCC, Barcelona, Spain) were validated by analysis 
of STRs (GenePrint® 10 System, Promega, Barcelona, 
Spain) and checked for mycoplasma contamination by 
PCR as previously reported [40]. Cells were maintained 
in Dulbecco’s Modified Eagle Medium (Sigma, San 
Louis, MO) supplemented with 10% fetal bovine serum, 
1% antibiotic-antimycotic and 2mM L-glutamine, in a 
constant atmosphere with 37ºC and 5% CO2. sst5TMD4 
stably-transfected cells and their respective mock control 
(empty pCDNA3.1 plasmid transfected cells) have been 
previously generated and validated [10].
Breast cancer xenografts model
Animal maintenance and experiments were carried 
out following the European Regulation for Animal Care 
under the approval of the University of Cordoba Research 
Ethics Committee. Six-week-old female athymic Swiss 
nu/nu mice were subcutaneously grafted in the flank with 
2x106 mock- or sst5TMD4-stably transfected MCF-7 cells 
(n=4-5 mice per condition). Tumor growth was monitored 
weekly during 3 months. Each tumor was dissected and 
different pieces were snap-frozen for qPCR analysis 
or formalin-fixed and sectioned for histopathological 
examination after hematoxylin-eosin staining as 
previously described [10].
RNA extraction, reverse transcription and qPCR
RNA extraction, quantification, reverse-transcription 
as well as the development, validation and application of 
qPCR to measure the expression levels of different human 
transcripts have been previously reported elsewhere by our 
group [41-45]. Total RNA was extracted from paraffin-
embedded breast cancer samples, frozen xenografted 
tumors and cell lines using Trizol (Life Technologies, 
Barcelona, Spain) following the manufacturer’s protocol 
and subsequently treated with DNase (Promega, 
Barcelona, Spain). Total RNA concentration and purity 
was assessed using Nanodrop 2000 spectrophotometer 
(Thermo Scientific, Wilmington, NC, USA), and 
subsequently retro-transcribed using random hexamer 
primers and cDNA First Strand Synthesis kit (MRI 
Fermentas, Hanover, MD, USA). Complementary DNA 
derived from cell lines, xenografted tumors and breast 
cancer samples were amplified by quantitative real-time 
PCR (qPCR), where samples were run, in the same plate, 
against a standard curve to estimate mRNA copy number 
(1, 101, 102, 103, 104, 105, and 106 copies of synthetic 
cDNA template for each transcript) and a No-RT sample 
as a negative control. qPCR was performed using Brilliant 
II SYBR Green Master Mix in the Stratagene Mx3000p 
instrument (both from Agilent, La Jolla, CA, USA) as 
previously described [42-44]. Thermal profile consisted of 
a initial step at 95°C for 10 minutes, followed by 40 cycles 
of denaturation (95°C for 30 seconds), annealing (61°C 
for 1 minute), and extension (72°C for 30 seconds); and 
finally, a dissociation cycle to verify that only one product 
was amplified. To control for variations in the amount of 
RNA used and the efficiency of the reverse-transcription 
reaction and, the expression level (copy number) of each 
transcript was adjusted by ACTB expression levels. It 
should be noted that, as previously reported [43, 44] and 
based on the stringent criteria to maximize specificity 
and efficiency, the qPCR technique, as applied, can be 
used to accurately quantify copy numbers for all human 
transcripts included in this study (see list of primers used 
in Supplementary Table S4).
Microarray gene expression profile
Microarray experiments were performed using 
Human Whole Genome array V2 4*44K array G4845A 
(Agilent Technologies, Santa Clara, CA, USA). Four 
independent passages from stably-transfected sst5TMD4-
pCDNA3.1 and empty-pCDNA3.1 vector, used as control 
(mock), MFC7 cells were used. Total RNA from cell lines 
was isolated using Trizol reagent (Life Technologies) as 
indicated by the manufacturer. Purity of isolated RNA 
was evaluated spectrophotometrically by the A260/A280 
absorbance ratio. RNA was labeled and array hybridized 
using the Low RNA Linear Amplification Kit and the 
In Situ Hybridization Kit Plus (Agilent technologies), 
respectively, following manufacturer’s protocol. After 
hybridization and washing, the slides were scanned 
in an Axon GenePix Scanner (Axon Instruments) 
and analyzed using Feature Extraction Software 10.0 
(Agilent technologies). RNA samples from independent 
sst5TMD4-stably transfected cells were labeled with Cy5-
dUTP and equal concentration of each RNA from mock 
control cells were labeled with Cy3-dUTP. Differentially 
expressed genes in sst5TMD4-transfected MCF-7 cells vs. 
control (mock) cells were identified with GEPAS (Gene 
Expression Pattern Analysis Suite, http://gepas3.bioinfo.
cipf.es) selecting genes with a fold difference of at least 
two in all of the samples and standard deviation lower than 
0,5. Functional enrichment analysis was performed using 
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the FatiGO application (http://babelomics.bioinfo.cipf.
es). Microarray raw data tables have been deposited in the 
Gene Expression Omnibus.
VEGF determination by ELISA
VEGF concentration in the sst5TMD4- and mock-
transfected MCF-7 culture media was determined using 
a commercial human VEGF ELISA kit (VEGF human 
ELISA kit; Cat. number: KHG0112; Life Technologies), 
following the manufacturer’s instructions. The information 
regarding specificity, detectability and reproducibility for 
the assay can be accessed at the company website.
Mammosphere formation assay
Mammosphere formation assays were developed 
following previously published protocols [46]. Briefly, 
10.000 sst5TMD4- and mock-transfected MCF-7 or MDA-
MB-231 cells were seeded (in triplicate) in 6-well plates 
pretreated with Poly(2-hydroxyethyl methacrylate) in 
2ml DMEM/F12 without phenol red. Culture media was 
supplemented with recombinant epithelial growth factor, 
B27 supplement and Gentamicin/Amphotericin B. After 
seven days of incubation at 37ºC, 5%CO2, the number of 
mammospheres was counted using an inverted microscope.
Western blotting
Xenografted tumors were processed for the detection 
of sst5TMD4 and VEGF by western blot using standard 
procedures [10]. Specifically, proteins were extracted from 
a tumoral piece using pre-warmed SDS-DTT sample buffer 
(62,5mM Tris-HCl, 2% SDS, 20% glicerol, 100mM DTT 
and 0,005% bromophenol blue) followed by sonication 
for 10 sec and boiling for 5 min at 95º C. Proteins were 
separated by SDS-PAGE and transferred to nitrocellulose 
membranes (Millipore). Membranes were blocked with 5% 
non-fat dry milk in Tris-buffered saline/0.05% Tween 20 
and incubated with the rabbit polyclonal antisera against 
human sst5TMD4 previously described [6, 10] or the 
specific goat anti-human VEGF antibody (AB-293-NA; 
R&D systems, Minneapolis, MN, USA) and the appropriate 
secondary antibodies (anti-rabbit or anti-goat IgG-HRP; 
Santa Cruz Biotechnology, Dallas, TX, USA). Proteins 
were developed using an enhanced chemiluminescence 
detection system (GE Healthcare, Madrid, Spain) with dyed 
molecular weight markers. A densitometric analysis of the 
bands was carried out with ImageJ software [47] using total 
protein loading (Ponceau staining) as normalizing factor as 
previously reported elsewere [48].
Immunohistochemical and 
immunohistofluorescence analysis
Xenografted tumors were processed for the 
detection of VEGF by immunohistofluorescence using 
standard procedures [10]. Specifically, a tumoral piece 
was formalin-fixed and paraffin-embedded. After antigen-
retrieval, sections were incubated with a specific anti-
human VEGF antibody (AB-293-NA; R&D systems) and 
the appropriate fluorescence-labeled secondary antibody 
(Donkey Anti-Goat IgG Alexa Fluor 488; ab150129; 
Abcam, Cambridge, UK). Signal intensity was determined 
using the ImageJ software [47].
sst5TMD4 and CD34 immunohistochemical 
staining of the human breast cancer samples was 
performed by the LSAB (Dako) method with a heat-
induced antigen retrieval step. Briefly, sections were 
immersed in boiling 10mM sodium citrate at pH 6.0 for 
3 min in a pressure cooker. Rabbit polyclonal antisera 
against human sst5TMD4 previously described [6, 10] 
and monoclonal mouse Anti-Human CD34 Class II (Clone 
QBEnd 10, Dako) were used as primary antibodies, and 
goat anti-rabbit (ThermoScientific, Barcelona, Spain) 
and rabbit anti-mouse (ThermoScientific) as secondary 
antibodies. The antibodies were used at 1:1000 dilutions. 
The primary antibodies were omitted in the negative 
controls. sst5TMD4 staining were categorized as low or 
high expression refers to the normal sst5TMD4 staining. 
CD34 staining was categorized as low or high with respect 
to normal mammary tissue.
Determination of blood vessels in the 
xenografted tumors
Xenografted tumors were processed for the 
quantification of blood vessel density using a standard 
histopathological procedure [49]. Specifically, a tumor 
piece was formalin-fixed and paraffin-embedded followed 
by haematoxylin and eosin staining. Vascular density was 
determined by counting the number of visible vessels per 
20x objective tumor-full fields from a minimum of 5 fields 
per each of the 4-5 animals per genotype.
Statistical analysis
For in vitro experiments, data are expressed as 
mean ± SEM obtained from, at least, three separate, 
independent experiments carried out in different days and 
with different cell preparations. Statistical analysis was 
carried out using Student’s t-test. For in vivo xenografts 
experiments, data are expressed as mean ± SEM obtained 
from n=4-5 animals. Statistical analysis was carried out 
using Student’s t-test. For the analysis of human breast 
carcinoma data, samples were categorized in low and 
high sst5TMD4 levels according to median sst5TMD4 
expression levels. Differences in the expression of 
angiogenic markers between both groups were assessed 
by Student’s t-test. Correlations between the expression 
of sst5TMD4 and angiogenic markers was assessed by 
Pearson´s correlation test. Significant correlations between 
categorized sst5TMD4 mRNA/protein expression, CD34 
IHC expression, presence of metastasis and disease-free 
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survival were studied using Chi-square and Long-rank-p-
value methods. Statistical analyses were carried out with 
GraphPad Prism 6 and SPSS 17.0 (IBM). P-values smaller 
than 0.05 were considered statistically significant.
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